News - Lipitor, Markets & Marketing


Popular Filters

$30 billion of fresh opportunities for Rx-to-OTC switch in USA


The US Food and Drug Administration has recently created the Non-prescription Safe Use Regulatory Expansion…

LipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRegulation

Mylan starts selling generic Lipitor in Europe; to buy back shares


US generic drug major Mylan's (Nasdaq: MYL) shares 2.2% to $21.55 in morning last Friday after the company…

atorvastatinCardio-vascularEuropeFinancialGenericsLipitorMarkets & MarketingMylan Laboratories

Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry


The German subsidiary of India's Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday…

atorvastatinBasics GmbHCardio-vascularDaiichi SankyoEuropeGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

Lipitor and strategic collapse at Pfizer, a consultants view


Now global pharma behemoth Pfizer (NYSE: PFE) spent $114 billion in 2000 for a hostile takeover of Warner-Lambert,…

Cardio-vascularFinancialLipitorMarkets & MarketingPfizerPharmaceutical

Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy


Reimbursement Intelligence, a USA-based market-research firm, has announced how payers predict the impact…

CaduetCardio-vascularGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

US launch of generic Lipitor confirms value of competition, says GPhA


Commenting on this week’s US roll out for generic copies of Pfizer blockbuster cholesterol lowerer…

GenericsLipitorMarkets & MarketingNorth AmericaPatentsPfizerRanbaxy LaboratoriesWatson Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top